2 results
Approved WMORecruiting
The primary objective of this study is to demonstrate efficacy of BIIB059compared with placebo in participants with active systemic lupuserythematosus (SLE), who are receiving background lupus standard ofcare (SOC) therapy in reducing disease…
Approved WMORecruiting
Primary Objective: Our objective is to validate the safety, measured by radiological disease activity, of personalized extended interval dosing of natalizumab to >=6 weeks (with an aim natalizumab trough concentration of 5 µg/ml) in a large…